TNSN08064A1 - Albumin fusion proteins - Google Patents

Albumin fusion proteins

Info

Publication number
TNSN08064A1
TNSN08064A1 TNP2008000064A TNSN08064A TNSN08064A1 TN SN08064 A1 TNSN08064 A1 TN SN08064A1 TN P2008000064 A TNP2008000064 A TN P2008000064A TN SN08064 A TNSN08064 A TN SN08064A TN SN08064 A1 TNSN08064 A1 TN SN08064A1
Authority
TN
Tunisia
Prior art keywords
fusion proteins
albumin fusion
nucleic acids
vectors
host cells
Prior art date
Application number
TNP2008000064A
Inventor
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Craig Rosen
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of TNSN08064A1 publication Critical patent/TNSN08064A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
TNP2008000064A 2005-08-12 2008-02-11 Albumin fusion proteins TNSN08064A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
TNSN08064A1 true TNSN08064A1 (en) 2009-07-14

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000064A TNSN08064A1 (en) 2005-08-12 2008-02-11 Albumin fusion proteins

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2425738T3 (en) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
MXPA06009072A (en) 2004-02-09 2007-03-29 Human Genome Sciences Inc Albumin fusion proteins.
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
MX2009002816A (en) * 2006-09-14 2009-05-28 Human Genome Sciences Inc Albumin fusion proteins.
US7884184B2 (en) 2007-01-30 2011-02-08 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
AU2009256547B2 (en) 2008-06-13 2014-07-10 Proyecto De Biomedicina Cima, S.L. Apo-A conjugates for the administration of biologically active compounds
UA105201C2 (en) * 2009-01-16 2014-04-25 Тева Фармасьютікал Індастріз Лтд. Use of recombinant human albumin-human granulocyte colony stimulating factor for preventing neutropenia or leukopenia
JP5936112B2 (en) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ Albumin variants and complexes
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
MX2012004793A (en) * 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Albumin variants.
CN106977608A (en) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 Albumin derivant and variant
BR112012029611A2 (en) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc bispecific fusion protein, pharmaceutical composition, method of treating tissue damage in an individual, method of promoting tissue regeneration or survival in an individual, and nucleic acid molecule
US20140072557A1 (en) * 2011-02-28 2014-03-13 National Cerebral And Cardiovascular Center Medicinal agent for suppressing malignant tumor metastasis
KR20140027307A (en) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572328B1 (en) 2011-10-21 2017-08-24 Abbvie Inc. COMBINATION OF AT LEAST TWO ANTIVIRAL AGENTS OF DIRECT ACTION AND RIBAVIRINA BUT NOT INTERFERED, FOR USE IN THE TREATMENT OF HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
HUE046396T2 (en) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
KR102008190B1 (en) 2012-02-15 2019-08-07 바이오버라티브 테라퓨틱스 인크. Recombinant factor viii proteins
ES2935489T3 (en) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Factor VIII compositions and methods of preparation and use thereof
EP2825556B1 (en) 2012-03-16 2018-01-03 Albumedix A/S Albumin variants
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CN104427995A (en) 2012-06-08 2015-03-18 比奥根艾迪克Ma公司 Chimeric clotting factors
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
JP6603128B2 (en) 2012-07-11 2019-11-06 バイオベラティブ セラピューティクス インコーポレイテッド Complex of factor VIII with XTEN and von Willebrand factor protein and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
ES2753391T3 (en) 2014-10-14 2020-04-08 Halozyme Inc Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
EA201890423A1 (en) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
CN108367048B (en) 2015-10-02 2022-08-12 银溪制药股份有限公司 Bispecific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
BR112018015659A2 (en) 2016-02-01 2018-12-26 Bioverativ Therapeutics Inc optimized factor viii genes
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
MA46967A (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc METHODS OF TREATMENT OF HEMOPHILIC ARTHROPATHY USING CHEMERICAL COAGULATION FACTORS
MX2019006446A (en) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Methods of inducing immune tolerance to clotting factors.
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
BR112019015569A2 (en) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. FACTOR IX FUSION PROTEINS AND METHODS FOR THEIR PRODUCTION AND USE
MA50141A (en) * 2017-04-20 2020-07-29 Novo Nordisk As ALBUMIN FUSION PROTEIN PURIFICATION PROCESSES
JP7374883B2 (en) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド Nucleic acid molecules and their uses
CN111918674A (en) 2018-02-01 2020-11-10 比奥维拉迪维治疗股份有限公司 Use of lentiviral vectors expressing factor VIII
JP2021533753A (en) 2018-08-09 2021-12-09 バイオベラティブ セラピューティクス インコーポレイテッド Nucleic acid molecules and their use for non-viral gene therapy
CA3121786A1 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
EP4038182A1 (en) 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2022030580A1 (en) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Novel long-acting adrenomedullin derivative, method for producing same and pharmaceutical use thereof
WO2024080306A1 (en) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and physiologically-active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425738T3 (en) * 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
MXPA06009072A (en) * 2004-02-09 2007-03-29 Human Genome Sciences Inc Albumin fusion proteins.
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
ECSP088262A (en) 2008-05-30
AU2006280312A1 (en) 2007-02-22
NO20081233L (en) 2008-05-09
CA2618476A1 (en) 2007-02-22
KR20080071119A (en) 2008-08-01
EP1924596A4 (en) 2009-07-29
JP2009504157A (en) 2009-02-05
MA29836B1 (en) 2008-10-03
IL189246A0 (en) 2008-08-07
WO2007021494A2 (en) 2007-02-22
MX2008001865A (en) 2008-04-15
BRPI0614761A2 (en) 2009-05-19
EP1924596A2 (en) 2008-05-28
WO2007021494A3 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (en) Albumin fusion proteins.
WO2007146038A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2001079443A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
HK1205193A1 (en) Recombinant n-glycosylated proteins from procaryotic cells n-
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EA201270758A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
EA201171220A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
EA201990619A1 (en) FGF21 MUTANTS AND THEIR APPLICATION
IN2012DN02981A (en)
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
WO2006017355A3 (en) Improved aprotinin variants
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2002097110A3 (en) TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins